Natural Killer Cell-Mediated Cytotoxicity Shapes the Clonal Evolution of B-cell Leukemia
The term cancer immunoediting describes the dual role by which the immune system can suppress and promote tumor growth and is divided into three phases: elimination, equilibrium, and escape. The role of NK cells has mainly been attributed to the elimination phase. Here, we show that NK cells play a...
Gespeichert in:
| Veröffentlicht in: | Cancer immunology research Jg. 13; H. 3; S. 430 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
04.03.2025
|
| Schlagworte: | |
| ISSN: | 2326-6074, 2326-6074 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | The term cancer immunoediting describes the dual role by which the immune system can suppress and promote tumor growth and is divided into three phases: elimination, equilibrium, and escape. The role of NK cells has mainly been attributed to the elimination phase. Here, we show that NK cells play a role in all three phases of cancer immunoediting. Extended co-culturing of DNA-barcoded mouse BCR/ABLp185+ B-cell acute lymphoblastic leukemia (B-ALL) cells with NK cells allowed for a quantitative measure of NK cell-mediated immunoediting. Although most tumor cell clones were efficiently eliminated by NK cells, a certain fraction of tumor cells harbored an intrinsic primary resistance. Furthermore, DNA barcoding revealed tumor cell clones with secondary resistance, which stochastically acquired resistance to NK cells. NK cell-mediated cytotoxicity put a selective pressure on B-ALL cells, which led to an outgrowth of primary and secondary resistant tumor cell clones, which were characterized by an IFNγ signature. Besides well-known regulators of immune evasion, our analysis of NK cell-resistant tumor cells revealed the upregulation of genes, including lymphocyte antigen 6 complex, locus A (Ly6a), which we found to promote leukemic cell resistance to NK cells. Translation of our findings to the human system showed that high expression of LY6E on tumor cells impaired their physical interaction with NK cells and led to worse prognosis in patients with leukemia. Our results demonstrate that tumor cells are actively edited by NK cells during the equilibrium phase and use different avenues to escape NK cell-mediated eradication. |
|---|---|
| AbstractList | The term cancer immunoediting describes the dual role by which the immune system can suppress and promote tumor growth and is divided into three phases: elimination, equilibrium, and escape. The role of NK cells has mainly been attributed to the elimination phase. Here, we show that NK cells play a role in all three phases of cancer immunoediting. Extended co-culturing of DNA-barcoded mouse BCR/ABLp185+ B-cell acute lymphoblastic leukemia (B-ALL) cells with NK cells allowed for a quantitative measure of NK cell-mediated immunoediting. Although most tumor cell clones were efficiently eliminated by NK cells, a certain fraction of tumor cells harbored an intrinsic primary resistance. Furthermore, DNA barcoding revealed tumor cell clones with secondary resistance, which stochastically acquired resistance to NK cells. NK cell-mediated cytotoxicity put a selective pressure on B-ALL cells, which led to an outgrowth of primary and secondary resistant tumor cell clones, which were characterized by an IFNγ signature. Besides well-known regulators of immune evasion, our analysis of NK cell-resistant tumor cells revealed the upregulation of genes, including lymphocyte antigen 6 complex, locus A (Ly6a), which we found to promote leukemic cell resistance to NK cells. Translation of our findings to the human system showed that high expression of LY6E on tumor cells impaired their physical interaction with NK cells and led to worse prognosis in patients with leukemia. Our results demonstrate that tumor cells are actively edited by NK cells during the equilibrium phase and use different avenues to escape NK cell-mediated eradication.The term cancer immunoediting describes the dual role by which the immune system can suppress and promote tumor growth and is divided into three phases: elimination, equilibrium, and escape. The role of NK cells has mainly been attributed to the elimination phase. Here, we show that NK cells play a role in all three phases of cancer immunoediting. Extended co-culturing of DNA-barcoded mouse BCR/ABLp185+ B-cell acute lymphoblastic leukemia (B-ALL) cells with NK cells allowed for a quantitative measure of NK cell-mediated immunoediting. Although most tumor cell clones were efficiently eliminated by NK cells, a certain fraction of tumor cells harbored an intrinsic primary resistance. Furthermore, DNA barcoding revealed tumor cell clones with secondary resistance, which stochastically acquired resistance to NK cells. NK cell-mediated cytotoxicity put a selective pressure on B-ALL cells, which led to an outgrowth of primary and secondary resistant tumor cell clones, which were characterized by an IFNγ signature. Besides well-known regulators of immune evasion, our analysis of NK cell-resistant tumor cells revealed the upregulation of genes, including lymphocyte antigen 6 complex, locus A (Ly6a), which we found to promote leukemic cell resistance to NK cells. Translation of our findings to the human system showed that high expression of LY6E on tumor cells impaired their physical interaction with NK cells and led to worse prognosis in patients with leukemia. Our results demonstrate that tumor cells are actively edited by NK cells during the equilibrium phase and use different avenues to escape NK cell-mediated eradication. The term cancer immunoediting describes the dual role by which the immune system can suppress and promote tumor growth and is divided into three phases: elimination, equilibrium, and escape. The role of NK cells has mainly been attributed to the elimination phase. Here, we show that NK cells play a role in all three phases of cancer immunoediting. Extended co-culturing of DNA-barcoded mouse BCR/ABLp185+ B-cell acute lymphoblastic leukemia (B-ALL) cells with NK cells allowed for a quantitative measure of NK cell-mediated immunoediting. Although most tumor cell clones were efficiently eliminated by NK cells, a certain fraction of tumor cells harbored an intrinsic primary resistance. Furthermore, DNA barcoding revealed tumor cell clones with secondary resistance, which stochastically acquired resistance to NK cells. NK cell-mediated cytotoxicity put a selective pressure on B-ALL cells, which led to an outgrowth of primary and secondary resistant tumor cell clones, which were characterized by an IFNγ signature. Besides well-known regulators of immune evasion, our analysis of NK cell-resistant tumor cells revealed the upregulation of genes, including lymphocyte antigen 6 complex, locus A (Ly6a), which we found to promote leukemic cell resistance to NK cells. Translation of our findings to the human system showed that high expression of LY6E on tumor cells impaired their physical interaction with NK cells and led to worse prognosis in patients with leukemia. Our results demonstrate that tumor cells are actively edited by NK cells during the equilibrium phase and use different avenues to escape NK cell-mediated eradication. |
| Author | Dopa, Sara Halbritter, Florian Emminger, Dominik Sippl, Lisa Schinnerl, Dagmar Shoeb, Mohamed R David, Faith O Buri, Michelle C Schumacher, Ton N Lehner, Manfred Dupanovic, Alma Koenig, Xaver Baik, Hayeon Kovacic, Boris Gotthardt, Dagmar Hall-Glenn, Faith Stofner, Susanne Bykov, Aleksandr Poetsch, Anna R Putz, Eva M Cosgrove, Jason Urbanus, Jos Repiscak, Peter Perié, Leïla |
| Author_xml | – sequence: 1 givenname: Michelle C orcidid: 0000-0001-7261-0201 surname: Buri fullname: Buri, Michelle C organization: St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria – sequence: 2 givenname: Mohamed R orcidid: 0000-0002-8660-6825 surname: Shoeb fullname: Shoeb, Mohamed R organization: St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria – sequence: 3 givenname: Aleksandr orcidid: 0000-0003-4532-9865 surname: Bykov fullname: Bykov, Aleksandr organization: St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria – sequence: 4 givenname: Peter orcidid: 0000-0002-7335-8324 surname: Repiscak fullname: Repiscak, Peter organization: St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria – sequence: 5 givenname: Hayeon orcidid: 0000-0003-0907-1334 surname: Baik fullname: Baik, Hayeon organization: St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria – sequence: 6 givenname: Alma orcidid: 0009-0005-3318-7996 surname: Dupanovic fullname: Dupanovic, Alma organization: St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria – sequence: 7 givenname: Faith O orcidid: 0009-0003-1160-4213 surname: David fullname: David, Faith O organization: Center for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, Vienna, Austria – sequence: 8 givenname: Boris orcidid: 0000-0002-1148-4149 surname: Kovacic fullname: Kovacic, Boris organization: St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria – sequence: 9 givenname: Faith orcidid: 0009-0008-2401-7102 surname: Hall-Glenn fullname: Hall-Glenn, Faith organization: St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria – sequence: 10 givenname: Sara orcidid: 0009-0007-9305-9421 surname: Dopa fullname: Dopa, Sara organization: Center for Physiology and Pharmacology, Department of Neurophysiology and Pharmacology, Medical University of Vienna, Vienna, Austria – sequence: 11 givenname: Jos orcidid: 0000-0003-3074-8477 surname: Urbanus fullname: Urbanus, Jos organization: Division of Molecular Oncology & Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 12 givenname: Lisa orcidid: 0009-0008-2814-5515 surname: Sippl fullname: Sippl, Lisa organization: St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria – sequence: 13 givenname: Susanne orcidid: 0009-0007-0116-1331 surname: Stofner fullname: Stofner, Susanne organization: St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria – sequence: 14 givenname: Dominik orcidid: 0000-0002-0687-5778 surname: Emminger fullname: Emminger, Dominik organization: Christian Doppler Laboratory for Next Generation CAR T Cells, Vienna, Austria – sequence: 15 givenname: Jason orcidid: 0000-0003-3121-2009 surname: Cosgrove fullname: Cosgrove, Jason organization: Institut Curie, Université PSL, Sorbonne Université, CNRS UMR168, Laboratoire Physico Chimie Curie, Paris, France – sequence: 16 givenname: Dagmar orcidid: 0000-0003-4918-9302 surname: Schinnerl fullname: Schinnerl, Dagmar organization: St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria – sequence: 17 givenname: Anna R orcidid: 0000-0003-3056-4360 surname: Poetsch fullname: Poetsch, Anna R organization: Biomedical Genomics, Biotechnology Center, Center for Molecular and Cellular Bioengineering, Technische Universität Dresden, Dresden, Germany – sequence: 18 givenname: Manfred orcidid: 0000-0002-5776-4218 surname: Lehner fullname: Lehner, Manfred organization: Christian Doppler Laboratory for Next Generation CAR T Cells, Vienna, Austria – sequence: 19 givenname: Xaver orcidid: 0000-0002-2423-4966 surname: Koenig fullname: Koenig, Xaver organization: Center for Physiology and Pharmacology, Department of Neurophysiology and Pharmacology, Medical University of Vienna, Vienna, Austria – sequence: 20 givenname: Leïla orcidid: 0000-0003-0798-4498 surname: Perié fullname: Perié, Leïla organization: Institut Curie, Université PSL, Sorbonne Université, CNRS UMR168, Laboratoire Physico Chimie Curie, Paris, France – sequence: 21 givenname: Ton N orcidid: 0000-0003-0517-8804 surname: Schumacher fullname: Schumacher, Ton N organization: Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands – sequence: 22 givenname: Dagmar orcidid: 0000-0002-8416-1236 surname: Gotthardt fullname: Gotthardt, Dagmar organization: Institute of Pharmacology, University of Veterinary Medicine Vienna, Vienna, Austria – sequence: 23 givenname: Florian orcidid: 0000-0003-2452-4784 surname: Halbritter fullname: Halbritter, Florian organization: St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria – sequence: 24 givenname: Eva M orcidid: 0000-0002-9990-4477 surname: Putz fullname: Putz, Eva M organization: Center for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, Vienna, Austria |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39642167$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkG9LwzAQxoNM3Jz7CEpe-iYzlyZZ-1LL1OFU8A_4rqTtlUWzZrapuG9vhxM8Hrjj-D0Pxx2TQe1rJOQU-BRAxRciEppprvU0XTwxIRmHODkgo_1-Jgf_5iGZtO077yuOJSh5RIZRoqUAPRuRtwcTusY4emedw4am6By7x9KagCVNt8EH_20LG7b0eWU22NKwQpo6X_ee-Zd3XbC-pr6iV6zovXSJ3QeurTkhh5VxLU72fUxer-cv6S1bPt4s0sslK6RUgWkEAYqDSYDniHnCy1znosJIGjBlmUguYZYXCedQyLgSPN8RqlRFUYEGMSbnv7mbxn922IZsbdvdJaZG37VZBFKrXirq0bM92uVrLLNNY9em2WZ_3xA_smJkng |
| CitedBy_id | crossref_primary_10_1080_2162402X_2025_2546443 |
| ContentType | Journal Article |
| Copyright | 2024 American Association for Cancer Research. |
| Copyright_xml | – notice: 2024 American Association for Cancer Research. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1158/2326-6066.CIR-24-0189 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2326-6074 |
| ExternalDocumentID | 39642167 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Dr. Mildred Scheel Stiftung für Krebsforschung – fundername: Austrian Science Fund FWF grantid: WKP 132 – fundername: Austrian Science Fund FWF grantid: I 4649 – fundername: Austrian Science Fund FWF grantid: P 31563 – fundername: Austrian Science Fund FWF grantid: TAI 732 – fundername: Österreichischen Akademie der Wissenschaften (ÖAW) grantid: #25905 – fundername: Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF) grantid: 20-17258 – fundername: Austrian Science Fund FWF grantid: TAI 454 – fundername: Fellinger Krebsforschung – fundername: Austrian Science Fund (FWF) grantid: 10.55776/TAI454 |
| GroupedDBID | 53G AENEX AFHIN AFUMD ALMA_UNASSIGNED_HOLDINGS CGR CUY CVF EBS ECM EIF NPM OK1 RCR RHI 7X8 |
| ID | FETCH-LOGICAL-c445t-6e121501a910beeb90db6b2fe34a1add940417bc9001c48f20b0db65d5ccf1612 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 1 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001437320000004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2326-6074 |
| IngestDate | Thu Sep 04 15:49:52 EDT 2025 Sat May 31 02:12:48 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | 2024 American Association for Cancer Research. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c445t-6e121501a910beeb90db6b2fe34a1add940417bc9001c48f20b0db65d5ccf1612 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-7261-0201 0000-0002-5776-4218 0009-0007-9305-9421 0000-0003-0907-1334 0000-0003-4918-9302 0000-0003-2452-4784 0000-0003-4532-9865 0009-0008-2814-5515 0000-0003-0798-4498 0000-0002-7335-8324 0000-0003-3121-2009 0000-0003-3074-8477 0009-0003-1160-4213 0009-0008-2401-7102 0000-0002-8660-6825 0009-0005-3318-7996 0009-0007-0116-1331 0000-0002-2423-4966 0000-0002-8416-1236 0000-0002-9990-4477 0000-0002-0687-5778 0000-0003-3056-4360 0000-0003-0517-8804 0000-0002-1148-4149 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7617306 |
| PMID | 39642167 |
| PQID | 3146546553 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3146546553 pubmed_primary_39642167 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-03-04 |
| PublicationDateYYYYMMDD | 2025-03-04 |
| PublicationDate_xml | – month: 03 year: 2025 text: 2025-03-04 day: 04 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cancer immunology research |
| PublicationTitleAlternate | Cancer Immunol Res |
| PublicationYear | 2025 |
| SSID | ssj0000884154 |
| Score | 2.3688776 |
| Snippet | The term cancer immunoediting describes the dual role by which the immune system can suppress and promote tumor growth and is divided into three phases:... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 430 |
| SubjectTerms | Animals Cell Line, Tumor Clonal Evolution - immunology Coculture Techniques Cytotoxicity, Immunologic - immunology Humans Killer Cells, Natural - immunology Killer Cells, Natural - metabolism Leukemia, B-Cell - genetics Leukemia, B-Cell - immunology Leukemia, B-Cell - pathology Mice Mice, Inbred C57BL Tumor Escape |
| Title | Natural Killer Cell-Mediated Cytotoxicity Shapes the Clonal Evolution of B-cell Leukemia |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39642167 https://www.proquest.com/docview/3146546553 |
| Volume | 13 |
| WOSCitedRecordID | wos001437320000004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwEA_qRHzx-2N-EcHXaJumafskWjYU3Rh-wN5Gk15xONvpuuH-ey9dpm8i-JKHkJZwudz9uNzdj5AzcFKZahUxKcFnIjRE7gE4jEs8_ECnUvEZ2UTQbofdbtSxAbeRTauc28TKUKeFNjHyC88VFXG3710O35lhjTKvq5ZCY5HUPIQyRquDbvgdY8EbhP5JVPxyXDKJ7tIW8bh-eGHnpDyPbx8YN8kY4S9As3I4zfX_bnWDrFmoSa9murFJFiDfIist-5i-TbrtpGq6Qe-qekAaw2DAWhV1B6Q0npZFWXzi2nJKH1-SIYwogkUaDwx2p42J1VlaZPSamfg_vYfxK7z1kx3y3Gw8xTfMEi0wLYRfMgmmx4TjJogdFICKnFThIWXgicRFAxgJR7iB0hH6NC3CjDvKrPBTX-sMISPfJUt5kcM-oTpSWjmghavw356MED76XKRBwl3T675OTucy66Eim90lORTjUe9HanWyNxN8bzjruNHzIlOPK4ODP3x9SFa54eg1eWLiiNQyvMZwTJb1pOyPPk4qDcGx3Wl9AU5zwvs |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Natural+Killer+Cell-Mediated+Cytotoxicity+Shapes+the+Clonal+Evolution+of+B-cell+Leukemia&rft.jtitle=Cancer+immunology+research&rft.au=Buri%2C+Michelle+C&rft.au=Shoeb%2C+Mohamed+R&rft.au=Bykov%2C+Aleksandr&rft.au=Repiscak%2C+Peter&rft.date=2025-03-04&rft.eissn=2326-6074&rft.volume=13&rft.issue=3&rft.spage=430&rft_id=info:doi/10.1158%2F2326-6066.CIR-24-0189&rft_id=info%3Apmid%2F39642167&rft_id=info%3Apmid%2F39642167&rft.externalDocID=39642167 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2326-6074&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2326-6074&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2326-6074&client=summon |